Exhaustion of chronically stimulated CD8(+) T cells is a significant obstacle to immune control of chronic infections or tumors. Although coinhibitory checkpoint blockade with anti-programmed death ligand 1 (PD-L1) Ab can restore functions to exhausted T cell populations, recovery is often incomplete and dependent upon the pool size of a quiescent T-bet(high) subset that expresses lower levels of PD-1. In a model in which unhelped, HY-specific CD8(+) T cells gradually lose function following transfer to male bone marrow transplantation recipients, we have explored the effect of shifting the balance away from coinhibition and toward costimulation by combining anti-PD-L1 with agonistic Abs to the TNFR superfamily members, OX40 and CD27. Sever...
Adoptive cellular immunotherapy using in vitro expanded CD8+ T cells shows promise for tumour immuno...
Peripheral mechanisms of self-tolerance often depend on the quiescent state of the immune system. To...
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination aga...
Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy, yet the freq...
Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8+ T cells, resulting in tumor regre...
The protective capability of tumor antigen-specific T cells is regulated by costimulatory and inhibi...
CD8+ T cells can kill cancer cells but are tightly regulated by receptors that confer positive or ne...
International audienceAlthough understanding of T-cell exhaustion is widely based on mouse models, i...
<div><p>Adoptive cellular immunotherapy using in vitro expanded CD8<sup>+</sup> T cells shows promis...
Adoptive cellular immunotherapy using in vitro expanded CD8+ T cells shows promise for tumour immuno...
Programmed T cell differentiation is critically influenced by the complement of costimulatory and co...
Naive T cells require signals from multiple costimulatory receptors to acquire full effector functio...
Chronic antigenic stimulation leads to T cell exhaustion, which drastically dampens T cell effector ...
Cancer immunotherapies targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4...
The therapeutic success of adoptive therapy with chimeric antigen receptor (CAR) engineered T cells ...
Adoptive cellular immunotherapy using in vitro expanded CD8+ T cells shows promise for tumour immuno...
Peripheral mechanisms of self-tolerance often depend on the quiescent state of the immune system. To...
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination aga...
Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy, yet the freq...
Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8+ T cells, resulting in tumor regre...
The protective capability of tumor antigen-specific T cells is regulated by costimulatory and inhibi...
CD8+ T cells can kill cancer cells but are tightly regulated by receptors that confer positive or ne...
International audienceAlthough understanding of T-cell exhaustion is widely based on mouse models, i...
<div><p>Adoptive cellular immunotherapy using in vitro expanded CD8<sup>+</sup> T cells shows promis...
Adoptive cellular immunotherapy using in vitro expanded CD8+ T cells shows promise for tumour immuno...
Programmed T cell differentiation is critically influenced by the complement of costimulatory and co...
Naive T cells require signals from multiple costimulatory receptors to acquire full effector functio...
Chronic antigenic stimulation leads to T cell exhaustion, which drastically dampens T cell effector ...
Cancer immunotherapies targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4...
The therapeutic success of adoptive therapy with chimeric antigen receptor (CAR) engineered T cells ...
Adoptive cellular immunotherapy using in vitro expanded CD8+ T cells shows promise for tumour immuno...
Peripheral mechanisms of self-tolerance often depend on the quiescent state of the immune system. To...
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination aga...